Science and finance expert
08.07.2014 - Will Lewis has joined Uniqure’s supervisory board in June 2014. The human gene therapy specialist company expects to profit from Lewis’ expertise in both scientific and financial aspects of management as well as experience in orphan diseases.
Will Lewis has more than 20 years of executive experience in the pharmaceutical and finance industries both in the US and internationally. He served as president and CEO and as a member of the Board of Directors of Insmed, a US biopharma company specialised in inhalation therapies for orphan lung diseases. He co-founded Aegerion Pharmaceuticals, where he also filled the role of president and chief financiel officer. Prior to Aegerion, Lewis spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo.
Lewis also serves as a member of the board of directors of Oberlin College and is a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Jörn Aldag, CEO of uniQure, commented “[Lewis’] exceptional experience in the field of orphan diseases as well as his broad knowledge of the US and European financial markets will be of high value to the company.”